Raphael Pharmaceutical (RAPH) Non-Current Debt (2024 - 2025)
Raphael Pharmaceutical (RAPH) posted Non-Current Debt of $34000.0 for Q4 2025, down 85.09% sequentially from $228000.0 in Q4 2024, and down 85.09% YoY from $228000.0 in Q4 2024.
Raphael Pharmaceutical (RAPH) Non-Current Debt (2024 - 2025) Analysis & Trends
Raphael Pharmaceutical has reported Non-Current Debt for 2 years, with the latest figure at $34000.0 in Q4 2025.
- Quarterly Non-Current Debt fell 85.09% year-over-year to $34000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34000.0 (down 85.09% YoY) and the FY2025 annual result came in at $34000.0, down 85.09% from the prior year.
- Non-Current Debt fell to $34000.0 in Q4 2025 per RAPH's latest filing, from $228000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $228000.0 in Q4 2024 and troughed at $34000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 130.00 Mn |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34,000.00 |
| Dec 31, 2024 | 228,000.00 |